Pharma15 Live! jumped at the chance to hear SnapIoT’s Ed Triebell discuss his company’s ground-breaking product, a software platform which allows users to seamlessly connect any smart device to any mobile device—and to any cloud.
Topics: Pharma15, clinical research, clinical trials, Disruptive Innovation, Conferences, digital, devices, BYOD, provisional device
Pharma15 Live! simply could not resist speaking with Jae Chung, founder of the “Turbo Tax for clinical trials start-up,” goBalto - and his furry friend, the Siberian Husky puppy aptly named Balto. Chung discussed his company’s mission to automate the laborious manual processes related to clinical trial start-up.
Topics: Pharma15, clinical research, clinical trials, Disruptive Innovation, Conferences, digital, Puppies
Georgia Mitsi spoke with BBK Worldwide’s Aaron Fleishman about her company’s newest app E.V.A — an engagement platform for patients who suffer from chronic neurological conditions. Says Mitsi: “It’s about evaluate, validate and act.”
Topics: Pharma15, clinical research, clinical trials, Disruptive Innovation, digital, devices, BYOD, provisional device, Most Viewed
During this year’s DPharm 2018, Pharma15 Live! met up with Hassan Kadhim, senior associate director and head of IT clinical trial planning and management at Boehringer Ingelheim, before his presentation on the company’s novel remote clinical trial in the respiratory space. Kadhim reflected about the huge changes that he’s seen in the industry just in the past year.
Topics: Pharma15, clinical research, clinical trials, Disruptive Innovation, Conferences, digital
In the ongoing battle of BYOD (bring-your-own-device) vs. provision devices, Zachary Javitt, CEO and co-founder of PillTracker, has firmly come down on one side.
Topics: Pharma15, clinical research, clinical trials, Disruptive Innovation, Conferences, digital
On Saturday November 3, BBK will be hosting the American Brain Tumor Association’s (ABTA) Boston regional meeting and resource fair at its offices in Needham, Mass. Founded in 1973, ABTA was the first national advocacy organization committed to funding brain tumor research and providing information and education to patients, caregivers, and their loved ones.
For 45 years, ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. In anticipation of the upcoming meeting in Boston, we spoke with ABTA Program Manager Christine Daly about the organization and their mission.
|
The first time I met Christine Pierre, we argued.
|
Pharma15 Live! sat down with David Levesque to discuss the goal and mission of Andaman7. Throughout the DPharm, one of the main topics was about new ways to allow patients to access their own data.
Topics: Pharma15, clinical research, clinical trials, Disruptive Innovation, Conferences, digital
You might have seen an article in the October 1 issue of The New York Times, titled “Uber, Lyft and the Urgency of Saving Money on Ambulances,” by Austin Frakt. The article pushed for alternative modes of transportation in medical situations – such as Uber and Lyft – as cost-saving measures.
CEO and Founding Principal of BBK Worldwide, Joan F. Bachenheimer, wrote a strong response to the article, which has been submitted to the Times as a Letter to the Editor. We would love to hear your thoughts on possible use of ride-sharing apps like Uber or Lyft for emergency services.
Topics: Patient Experience, Patient Engagement, Patient Retention, Patient Travel
Pharma15 Live! sat down Valerie Bowling, drug development industry researcher and founder of DPharm, during the conference to discuss this year’s presentations, and the very popular DPharm Idol competition:
Topics: Pharma15, clinical research, clinical trials, patient data, Disruptive Innovation, Conferences
She forcefully made the point that research sites were the most critical players in the clinical research enterprise. No sponsor could conduct quality research without quality investigators.